Clinical efficacy of casirivimab and imdevimab in preventing COVID-19 in the Omicron BA.5 subvariant epidemic: a retrospective study
CAS + IMD may be effective for post-exposure prophylaxis of COVID-19 during the Omicron BA.5 subvariant epidemic. However, prudent clinical use should consider the circulating variant profile. Further research is warranted to validate CAS + IMD's role in COVID-19 post-exposure prophylaxis.
Authors
- Mariko Ohtani
- Kazuhiro Tateda (ORCID: https://orcid.org/0000-0002-6200-6163)
- Takuya Yokoo
- Takahiro Matsumoto (ORCID: https://orcid.org/0000-0002-8985-0006)
- Shinobu Hirayama
- Hiroshi Yasuda (ORCID: https://orcid.org/0000-0003-4547-5213)
- Taito Miyazaki (ORCID: https://orcid.org/0000-0001-7239-8677)
- Sadako Yoshizawa (ORCID: https://orcid.org/0000-0001-5410-6511)
- Emi Sato (ORCID: https://orcid.org/0000-0001-9394-653X)
- Manabu Tomida
- Hinako Murakami
- Mayumi Tsukada
- Eriko Nishikawa
Institutions
- Toho University (JP)
- Toho University Omori Medical Center (JP)
Publication Details
- Journal
- Journal of Pharmaceutical Health Care and Sciences
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1186/s40780-025-00501-x
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.40